HeartMate 3 LVAD Clinical Evidence | Abbott
CARDIOVASCULAR
hamburger

Clinical Evidence

MOMENTUM 3 is the largest LVAD trial ever conducted demonstrating excellent survival and safety outcomes with HeartMate 3™ LVAD.*1 For the first time in LVAD history, 5-year data is available from this prospective randomized LVAD trial.2 

HEARTMATE 3 LVAD, a proven long-term, life-extending therapy for patients with advanced heart failure
 

Median survival
exceeding
5 years

FPO

58.4%
survival at
5 years

Nearly 60%

Life-prolonging therapy in a patient population who otherwise would not be expected to survive beyond 9 months2,3**

Life-prolonging therapy

Superiority of the HeartMate 3 LVAD driven by a reduction in hemocompatibility-related adverse events2

Reduction in adverse events

Survival comparable to higher-risk transplant patients2,4

 

Survival comparamble to higher-risk transplant patients

ELEVATE Registry

The ELEVATE Registry evaluated the real-world experience of the HeartMate 3 LVAD in a post-approval setting.5 5-year extended follow-up showed significant increase in 6-minute walk distance.
 

Significant Increase in 6-Minute Walk Distance5

Three silhouettes of figures walking along a football field representing the 6-minute walk test. Patients with HeartMate 3 LVAD saw over a two-fold increase in distance.

Quality-of-life improved significantly and was sustained through 5 years5

As measured by the EuroQoL-5 Dimensions-5 Levels (EQ-5D-5L) questionnaire

Quality-of-life improved

Improved Safety Profile5

Stroke
10.8% in first 2 years
3.6% in years 2-5

Thrombosis
1.1% at 5 years

All major event types were reduced in the 2-5 years follow-up period compared to 0-2 years, especially hemocompatiblity-related adverse events.

Get the HeartMate 3 LVAD Product Brochure

  • Manuals & Resources
    Manuals & Resources
  • Find a HeartMate 3 LVAD Center
    Find a HeartMate 3 LVAD Center
  • Customer Service
    Customer Service

*HeartMate 3 LVAD demonstrated superiority in event-free survival (primary endpoint) in the MOMENTUM 3 trial compared to HeartMate II™ LVAD.
**Patients on inotropes who did not receive a transplant or left ventricular assist device.

References

  1. Mehra M, Uriel N, Naka Y, et al. A Fully Magnetically Levitated Left Ventricular Assist Device-Final Report. N Engl J Med. 2019;380:1618-1627.
  2. Mehra MR, Goldstein DJ, Cleveland JC, et al. Five-Year Outcomes in Patients With Fully Magnetically Levitated vs Axial-Flow Left Ventricular Assist Devices in the MOMENTUM 3 Randomized Trial. JAMA. September 8, 2022. doi:10.1001/jama.2022.16197
  3. Hashim T, Sanam K, Revilla-Martinez M, et al. Clinical Characteristics and Outcomes of Intravenous Inotropic Therapy in Advanced Heart Failure. Circ Heart Fail. 2015;8(5):880-886.
  4. Kilic et al. Factors associated with 5-year survival in older heart transplant recipients. J Thorac Cardiovasc Surg 2012;143:468-74.
  5. Schmitto JD, Shaw S, Garbade J, et al. Long-Term Results in Real World Patients Treated with HeartMate 3 LVAD for Advanced Heart Failure: Data from the ELEVATE Registry. Presented at: European Association for Cardio-Thoracic Surgery (EACTS) Annual Meeting; October 8, 2022; Milan, Italy.
Indications, Safety & Warnings

MAT-2012644 v4.0

DO YOU WISH TO CONTINUE AND EXIT CARDIOVASCULAR.ABBOTT?

CONTENTS OF THE SITE ARE NOT UNDER THE CONTROL OF ABBOTT.

False
accessibility
© 2021 Abbott. All Rights Reserved. Please read the Legal Notice for further details.

Unless otherwise specified, all product and service names appearing in this Internet site are trademarks owned by or licensed to Abbott, its subsidiaries or affiliates. No use of any Abbott trademark, trade name, or trade dress in this site may be made without the prior written authorization of Abbott, except to identify the product or services of the company.

accessibility

DO YOU WISH TO CONTINUE AND EXIT CARDIOVASCULAR.ABBOTT?

CONTENTS OF THE SITE ARE NOT UNDER THE CONTROL OF ABBOTT.